Ken Griffin Aligos Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

3 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$0.35 - $1.07 $35 - $107	100 Added 50.0%	300 $0
Q1 2024 May 15, 2024	BUY	$0.64 - $1.13 $128 - $225	200 New	200 $0
Q4 2022 Feb 14, 2023	BUY	$0.89 - $28.0 $89 - $2,800	100 New	100 $0

37.7M

1.4K

300

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $751M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.